Sitagliptin/metformin
| Combination of | |
|---|---|
| Sitagliptin | Dipeptidyl peptidase-4 inhibitor |
| Metformin | Biguanide |
| Clinical data | |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG | |
Sitagliptin/metformin (trade name Janumet) is an anti-diabetic drug, being a combination drug of sitagliptin (a dipeptidyl peptidase-4 inhibitor) and metformin. It is used a third-line treatment for people who do not achieve control of their blood sugar with metformin alone, or after trying to add sulfonylurea, pioglitazone, or insulin to the treatment.[1]
As of 2018 the combination was marketed under several brand names, including Efficib, Janmet, Januet, Janumet, Jznumet, Ristaben Met, Ristfor, Siglimet, Sitamet, Sitar-M, Sliptin-M, Treviamet, and Velmetia.[2]
References
- ^ Hayes, J; Anderson, R; Stephens, JW (2016). "Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy". Drug Design, Development and Therapy. 10: 2263–70. doi:10.2147/DDDT.S93076. PMC 4958358. PMID 27486305.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ "International brands for Sitagliptin/metformin". Drugs.com. Retrieved 3 September 2018.
External links
Wikimedia Commons has media related to Sitagliptin metformin.
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |